A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function - Trial NCT05940402
Access comprehensive clinical trial information for NCT05940402 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cerevel Therapeutics, LLC and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cerevel Therapeutics, LLC
Timeline & Enrollment
Phase 1
Jul 24, 2023
Jun 01, 2025
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of Emraclidine,Maximum Observed Unbound Plasma Concentration (Cmax,u) of Emraclidine,Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of Emraclidine,Area Under the Unbound Plasma Concentration-time Curve from Time Zero to t (AUC0-t,u) of Emraclidine,Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Emraclidine,Area Under the Unbound Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf,u) of Emraclidine
Summary
The primary purpose of this study is to assess the effect of renal impairment on the
 pharmacokinetics (PK) of emraclidine following administration of a single oral dose in
 participants with mild, moderate, and severe renal impairment relative to matched
 participants with normal renal function.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05940402
Non-Device Trial